Myovant Sciences Appoints Ann Tomlin as Senior Vice President of Human Resources

Rhea-AI Summary

Myovant Sciences announced the appointment of Ann Tomlin as the new Senior Vice President of Human Resources, effective November 28, 2022. Tomlin brings over 25 years of HR experience, particularly in the pharmaceutical sector, and will focus on talent solutions and HR strategies globally. She has a strong background in organizational development and has previously held leadership roles at AbbVie. CEO David Marek expressed confidence in her ability to enhance Myovant’s people-first strategy during a pivotal growth phase.

Positive

• Appointment of Ann Tomlin, an experienced HR leader, may strengthen Myovant's organizational culture and employee engagement.
• Tomlin's proven track record in building high-performing teams could enhance Myovant's operational efficiency.

Negative

• Concerns about the transition period as Tomlin integrates into the role, potentially impacting continuity in HR strategies.

BASEL, Switzerland, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) today announced the appointment of Ann Tomlin as Senior Vice President of Human Resources. Beginning November 28, Ms. Tomlin will be responsible for developing talent solutions and human resources strategies across Myovant’s global functions. She will serve as a member of the Executive Committee and will report to David Marek, Myovant’s Chief Executive Officer.

Ms. Tomlin has over 25 years of human resources experience with a demonstrated history of working in pharmaceutical and biotech organizations building strategies and solutions across organizational and people development, employee recruitment, business goals and key performance indicators. She has a proven track record of driving innovative ideas to build a high-performing culture.

"We are delighted to welcome Ann to Myovant during this exciting time of the company’s growth," said David Marek, Chief Executive Officer of Myovant Sciences, Inc. “Her deep understanding of the importance of a people-first strategy and proven track record of driving innovative ideas to develop continuous high-performing teams will be invaluable to our commitment to improve the lives of patients.”

Ms. Tomlin joins Myovant from AbbVie, where she served as Head of HR for the South San Francisco Site and Oncology Early Development function leading the successful integration and culture transformation across three locations. She also led the HR organization redesign and talent strategy across US and Swiss entities for the Pharmacyclics integration with AbbVie. She spent over a decade in various HR leadership roles across global divisions at AbbVie, where she was responsible for designing and implementing performance management and culture initiatives to sustain performance and drive retention. Ann began her career at Abbott Laboratories, where she served in various senior leadership roles for over a decade. During her tenure at Abbott, she led the design of processes and tools for succession planning, career development, and high-potential rotational programs benefitting corporate-wide teams across 65+ countries.

"I am thrilled to join Myovant at this pivotal time for the company," said Ms. Tomlin, Senior Vice President for Human Resources of Myovant Sciences, Inc. "Myovant has proven to be an industry leader through its science, successful product launches and commitment to patient-centered transformative advocacy. I look forward to joining this purpose-driven team and culture that values collaboration, diversity, and commitment to the company's mission of redefining care for patients.”

Ms. Tomlin received her M.S. in Labor and Industrial Relations from Loyola University of Chicago and her B.A. in Communications from the University of Illinois at Urbana-Campaign.

About Myovant Sciences
Myovant Sciences aspires to redefine care for women and men through purpose-driven science, empowering medicines, and transformative advocacy worldwide. Founded in 2016, Myovant has executed multiple successful Phase 3 clinical trials across hormone-sensitive oncology and women’s health leading to five regulatory approvals in the United States and Europe. Myovant and its partners continue to file for additional indications of its lead products as well as continue further development of pipeline assets. Sumitovant Biopharma Ltd., a wholly owned subsidiary of Sumitomo Pharma Co., Ltd., is Myovant’s majority shareholder. For more information, please visit www.myovant.com.

Investor Contact:
Uneek Mehra
Chief Financial Officer
Myovant Sciences, Inc.
investors@myovant.com

Media Contact:
Noelle Cloud Dugan
Vice President, Corporate Communications
Myovant Sciences, Inc.
media@myovant.com

FAQ

Who is Ann Tomlin and what is her role at Myovant?

Ann Tomlin is appointed as the Senior Vice President of Human Resources at Myovant, starting November 28, 2022.

What experience does Ann Tomlin bring to Myovant?

Tomlin has over 25 years of HR experience in the pharmaceutical industry, including leadership roles at AbbVie.

What are the expected impacts of Ann Tomlin's appointment on Myovant?

Her appointment is expected to enhance talent development and employee engagement, supporting the company's growth.

When will Ann Tomlin begin her role at Myovant?

Ann Tomlin will start her role as Senior Vice President of Human Resources on November 28, 2022.